Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting

10/15/24 8:00:00 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $PALI alert in real time by email

Carlsbad, CA, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepted for poster presentation at ACG's 2024 Annual Scientific Meeting being held October 25-30, 2024 in Philadelphia, PA.

The American College of Gastroenterology (ACG) is a recognized leader in educating GI professionals and the general public about digestive disorders. For more information about the ACG Annual Meeting, please visit the conference website.

About Palisade Bio

Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.

Investor Relations Contact

JTC Team, LLC

Jenene Thomas

908-824-0775

[email protected]

Get the next $PALI alert in real time by email

Date	Price Target	Rating	Analyst
2/2/2022	$5.00	Buy	Ladenburg Thalmann
8/31/2021	$7.00	Buy	Maxim Group

Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting

Chat with this insight

Recent Analyst Ratings for $PALI

$PALI Market Insights

Live Market Insights

Palisade Bio shares are trading higher after the company announced that European Patent Office has issued a decision to grant notice for patent number 4,157,853 titled, "Gut Microbiota Bioactivated PDE4 Inhibitor Precursors."

Palisade Bio Announces European Patent Office Issued Decision To Grant Notice For Patent Number 4,157,853 Titled "Gut Microbiota Bioactivated PDE4 Inhibitor Precursors."

Palisade Bio shares are trading higher after the company announced the completion of the first Good Manufacturing Practice batch of its drug substance PALI-2108 and is on track to commence its Phase 1 human clinical study.

$PALI Press Releases

Fastest customizable press release news feed in the world

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

$PALI SEC Filings

$PALI Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

SEC Form S-1 filed by Palisade Bio Inc.

Palisade Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update

SEC Form 10-Q filed by Palisade Bio Inc.

Williams Donald Allen bought $4,863 worth of Comon Stock (1,000 units at $4.86) (SEC Form 4)

Finley John David bought $4,810 worth of shares (1,000 units at $4.81), increasing direct ownership by 13% to 8,437 units (SEC Form 4)

Finley John David bought $4,692 worth of shares (10,000 units at $0.47), increasing direct ownership by 13% to 84,649 units (SEC Form 4)

$PALI Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Wei Binxian

SEC Form 4 filed by Director Fischbein Margery B.

SEC Form 4 filed by Director Williams Donald Allen

$PALI Leadership Updates

Live Leadership Updates

Palisade Bio Appoints Margery Fischbein to its Board of Directors

Correction Notice of Palisade Bio's Press Release Announcing the Appointment of Clinical Advisory Board Members

Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders

$PALI Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Ladenburg Thalmann initiated coverage on Palisade Bio with a new price target

Maxim Group initiated coverage on Palisade Bio with a new price target

$PALI Large Ownership Changes

This live feed shows all institutional transactions in real time.

$PALI Financials

Live finance-specific insights

SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced the Extent and Severity of Post-Surgical Intraabdominal Adhesions by 93%

Recent Analyst Ratings for
$PALI

$PALI
Market Insights

$PALI
Press Releases

$PALI
SEC Filings

$PALI
Insider Purchases

$PALI
Insider Trading

$PALI
Leadership Updates

$PALI
Analyst Ratings

$PALI
Large Ownership Changes

$PALI
Financials